Fulcrum therapeutics enters into a collaboration and license agreement with sanofi for the development and commercialization of losmapimod in facioscapulohumeral muscular dystrophy

― sanofi receives exclusive rights to commercialize losmapimod in all territories outside the u.s.; fulcrum retains full u.s. commercialization rights ―

FULC Ratings Summary

FULC Quant Ranking